The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis

Brazilian Journal of Medical and Biological Research

Volumn 38, Issue 9, 2005, Pages 1409-1416

  Randon, R B ^a   Rohde, L E ^a   Comerlato, L ^a   Ribeiro, J P ^a,b   Manfro, R C ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Echocardiography; End stage renal failure; Left ventricular hypertrophy; Parathyroid hormone

Indexed keywords

HEMOGLOBIN; PARATHYROID HORMONE;

ADULT; AGE; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; PARATHYROID HORMONE BLOOD LEVEL; PREDICTION; SECONDARY HYPERPARATHYROIDISM; STATISTICAL SIGNIFICANCE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 24744435849     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2005000900016     Document Type: Article

References (29)

1. Parfrey PS, Harnett JD & Barre PE (1991). The natural history of myocardial disease in dialysis patients. Journal of the American Society of Nephrology, 2: 2-12.
2. Foley RN, Parfrey PS, Harnett JD et al. (1995). Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney International, 47: 186-192.
3. Harnett JD, Parfrey PS, Griffiths SM et al. (1988). Left ventricular hypertrophy in end-stage renal disease. Nephron, 48: 107-115.
4. Massry SG & Smogorzewski M (1996). The heart in uremia. Seminars in Nephrology, 16: 214-221.
5. Foley RN & Parfrey PS (1997). Cardiac disease in chronic uremia: clinical outcome and risk factors. Advances in Renal Replacement Therapy, 4: 234-248.
6. London GM, De Vernejoul MC, Fabiani F et al. (1997). Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney International, 32: 900-907.
7. Amann K & Ritz E (1997). Cardiac disease in chronic uremia: pathophysiology. Advances in Renal Replacement Therapy, 4: 212-224.
8. Avram MM, Sreedhara R, Avram DK et al. (1996). Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia. American Journal of Kidney Diseases, 28: 924-930.
9. Strozecki P, Adamowicz A, Nartowicz E et al. (2001). Parathormone, calcium, phosphorus and left ventricular structure and function in normotensive hemodialysis patients. Renal Failure, 23: 115-126.
10. Devereux RB, Alonso DR, Lutas EM et al. (1986). Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. American Journal of Cardiology, 57: 450-458.
11. Levy D, Savage DD, Garrison RJ et al. (1987). Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. American Journal of Cardiology, 59: 956-960.
12. Moss DW & Whitby LG (1975). A simplified heat-inativation curves of alkaline phosphatase isoenzymes in serum. Clinica Chimica Acta, 61: 63-71.
13. Rostand SG & Drüeke TB (1999). Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney International, 56: 383-392.
14. Stack AG & Saran R (2002). Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. American Journal of Kidney Diseases, 40: 1202-1210.
15. Endres DB, Villanueva R, Sharp Jr CF et al. (1989). Measurements of parathyroid hormone. Endocrinology and Metabolism Clinics of North America, 18: 611-629.
16. Harnett JD, Kent GM, Barre PE et al. (1994). Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. Journal of the American Society of Nephrology, 4: 1486-1490.
17. MacDougall IC, Lewis NP, Saunders MJ et al. (1990). Long-term cardiorespiratory effects on amelioration of renal anaemia by erythropoetin. Lancet, 335: 489-493.
18. Foley RN, Parfrey PS, Harnett JD et al. (1996). Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney International, 49: 1379-1385.
19. London GM (2002). Left ventricular alterations and end stage renal disease. Nephrology, Dialysis, Transplantation, 18 (Suppl 1): 29-36.
20. Cuspidi C, Lonati L, Sampieri L et al. (2000). Impact of blood pressure control on prevalence of left ventricular hypertrophy in treated hypertensive patients. Cardiology, 93: 149-154.
21. Mall G, Huther W, Schneider J et al. (1990). Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrology, Dialysis, Transplantation, 5: 39-44.
22. Mall G, Rambausek M, Neumeister A et al. (1988). Myocardial interstitial fibrosis in experimental uremia - implication for cardiac compliance. Kidney International, 33: 804-811.
23. Amann K, Ritz E, Wiest G et al. (1994). A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. Journal of the American Society of Nephrology, 4: 1814-1819.
24. Nappi S, Saha H, Virtanen V et al. (2000). Left ventricular structure and function in primary hyperparathyroidism before and after parathyroidectomy. Cardiology, 93: 229-233.
25. Saleh FN, Schirmer H, Sundsfjord J et al. (2003). Parathyroid hormone and left ventricular hypertrophy. European Heart Journal, 24: 2054-2060.
26. Andersson P, Rydberg E & Willenheimer R (2004). Primary hyperparathyroidism and heart disease - a review. European Heart Journal, 25: 1776-1787.
27. Dominiczak AF, Lyall F, Morton JJ et al. (1990). Blood pressure, left ventricular mass and intracellular calcium in primary hyperparathyroidism. Clinical Science, 78: 127-132.
28. Ferreira SR, Moises VA, Tavares A et al. (2002). Cardiovascular effects of successful renal transplantation: a 1-year sequential study of left ventricular morphology and function, and 24-hour blood pressure profile. Transplantation, 74: 1580-1587.
29. Chow KM, Szeto CC, Kum LC et al. (2003). Improved health-related quality of life and left ventricular hypertrophy among dialysis patients treated with parathyroidectomy. Journal of Nephrology, 16: 878-885.